CREATING A PREMIER GLOBAL PLATFORM FOR TARGETED CNS DRUG DELIVERY
– Sale agreement for Renishaw Neuro Solutions’ Neuroinfuse™ drug delivery system a key milestone as Neurochase prepares to use this pioneering CNS drug delivery device in a clinical trial planned for early 2026 –
Neurochase, a company developing innovative platform neurosurgical devices and providing consultancy services for targeted CNS drug delivery, and Renishaw Neuro Solutions Ltd, a company in the Renishaw Group specializing in stereotactic robotics and implantable drug-delivery systems, today (date) announced that they have entered into a definitive agreement for Neurochase to acquire key strategic device assets from Renishaw’s portfolio.
The deal sees UK-based Neurochase take exclusive ownership of Renishaw Neuro Solutions’ Neuroinfuse™ drug delivery system and all IP associated with the technology.
The Renishaw Neuroinfuse™ system comprises a bone anchored transcutaneous port through which therapies can be administered intermittently over months or years to brain targets via multiple cannulas. It has been successfully deployed in clinical trials for monthly infusions of neurotrophins to treat patients with Parkinson’s Disease and used under humanitarian approval for repeated delivery of chemotherapy directly into brainstem tumours in children.
The paediatric brain stem tumour known as Diffuse Intrinsic Pontine Glioma (DIPG) typically affects children between four and 10 years and they have a median survival of less than one year. In view of the survival benefit seen in children with DIPG who have received intermittent chemotherapy infusions using the Neuroinfuse™ system, Neurochase intends to use the system in a clinical trial planned for early-2026.
Sharon Kane, CEO of Neurochase, said: “The acquisition of Renishaw’s drug delivery device IP and the Neuroinfuse™ system is a significant strategic milestone for Neurochase. Not only will it bolster our already impressive product portfolio, but it will also enhance the Neurochase offering to pharmaceutical and biotech companies seeking both acute and chronic direct drug delivery solutions to the CNS.
More…
“Most importantly for everyone at Neurochase, this agreement will bring the company a step closer to its founding principle – to develop and deliver solutions that enable transformative therapies to reach the hundreds of millions of people across the world whose lives have been devastated by neurodegenerative, neuro oncological and other debilitating neurological conditions.”
The combined portfolio will be positioned to offer the most comprehensive suite of therapeutic delivery solutions available to the growing £1.5 billion addressable market for pre-clinical, clinical trial and commercial CNS drug delivery.
The agreement has been unanimously approved by the Boards of Directors of both companies and all relevant transfer activities will be completed by January 2026.
To find out more about Neurochase and its game-changing CED medical device and other services visit www.neurochase.com
Ends
About Neurochase
Neurochase is delivering transformative therapy solutions for companies tackling life-limiting and life-threatening neurological conditions, including MND, Parkinson’s, Huntington’s Disease and brain tumours. Established in 2020 by Founder and Chief Scientific Officer, Steven Gill, UK-based Neurochase is a world-leading authority in CNS drug delivery.
The company develops state-of-the-art, bespoke and globally scalable solutions for the pharmaceutical and biotech industries to enable the delivery of gene and cell therapies and other treatments safely and effectively.
